Three Bio4Dreams startups shaping the future of health
Milano Finanza recently published an article highlighting eight emerging startups committed to redefining the future of health through technological innovation.
Queste aziende italiane stanno sviluppando soluzioni avanzate in ambito health tech, affrontando sfide mediche complesse con approcci diagnostici e terapeutici all’avanguardia.
These Italian companies are developing advanced solutions in health tech, tackling complex medical challenges with cutting-edge diagnostic and therapeutic approaches.
Among them, BrainDTech, ChemiCare, and Evotion stand out—three innovative SMEs incubated and supported by Bio4Dreams. These startups are developing diagnostic and therapeutic solutions in areas such as neurodegenerative diseases, calcium regulation, and infant health monitoring, underscoring the importance of the Bio4Dreams ecosystem within the national Life Sciences innovation landscape.
Bio4Dreams startups selected by Milano Finanza
BrainDTech is developing an innovative diagnostic approach with its proprietary technology (MicroCATCH) to identify new biomarkers for neurodegenerative diseases such as Alzheimer’s, multiple sclerosis, and traumatic brain injury through early liquid biopsy.
ChemiCare is working on modulators of Store-Operated Calcium Entry (SOCE) to treat calcium-related disorders, such as Duchenne muscular dystrophy, for which its drug candidate recently received orphan drug designation from the FDA.
Evotion specializes in developing health-monitoring devices, with its flagship product, Momi—a wearable bracelet designed to monitor key vital parameters in children up to 5 years old.
The SME recently won a €157,000 grant, initiated hospital tests for its device, signed an agreement with La Molisana, and achieved overfunding in a crowdfunding campaign.
In the context of technological evolution, health tech is becoming a crucial pillar for the future of health, integrating medicine and innovation to improve disease prevention, diagnosis, and treatment. We are extremely proud that three of our leading companies—BrainDTech, ChemiCare, and Evotion—have been selected by a prestigious publication like Milano Finanza. This recognition confirms Bio4Dreams’ commitment to supporting startups capable of redefining public health and creating new opportunities for personalized medicine through advanced technologies.
Elisabetta Borello, Co-Founder e VP Strategy & External Relations di Bio4Dreams.
🔗 Read the full article on Milano Finanza
📗 Discover all the companies in our portfolio.